These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7125090)

  • 1. [Double-blind study on the effects of potassium canrenoate on perifocal edema in acute cerebral ischemia].
    Bidabé AM; Floras P; Orgogozo JM; Péré JM; Dartigues JF; Caillé JM
    Agressologie; 1982; 23(C):35-41. PubMed ID: 7125090
    [No Abstract]   [Full Text] [Related]  

  • 2. [Brain edema in neurosurgery. Trial with an aldosterone-antagonist (soldactone) (author's transl)].
    Anderes JP; de Tribolet N; Zander E
    Schweiz Rundsch Med Prax; 1977 Aug; 66(32):1020-6. PubMed ID: 556440
    [No Abstract]   [Full Text] [Related]  

  • 3. [Potassium canreonate in neurosurgical brain edema].
    Mille T; Rodriguez R; Baena Y
    Minerva Chir; 1975 Jul 15-31; 30(13-14):781-9. PubMed ID: 1221307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 5. [Indication and experience with an intravenously administered aldosterone-antagonist (soldactone) (author's transl)].
    Kirsch R
    Schweiz Rundsch Med Prax; 1975 Nov; 64(44):1414-7. PubMed ID: 1236699
    [No Abstract]   [Full Text] [Related]  

  • 6. [Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction].
    Denis B; Machecourt J; Denis MC; Morena H; Pellet J; Rossignol B; Martin-Noël P
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1014-22. PubMed ID: 116612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [False values of blood digoxin in patients with acute and chronic liver disease. Role of canrenoate potassium and comparison of radioimmunologic and immunoenzymatic methods].
    Nardoni A; di Piazza V; Moretti V; Copetti R; Trinco G; Geatti O
    Clin Ter; 1988 May; 125(4):287-90. PubMed ID: 2974364
    [No Abstract]   [Full Text] [Related]  

  • 9. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical study of potassium canrenoate on raised intracranial pressure.
    Node Y; Nakazawa S
    Adv Neurol; 1990; 52():557. PubMed ID: 2396562
    [No Abstract]   [Full Text] [Related]  

  • 11. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
    Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of canrenoate potassium on intraoperative disturbances of electrolyte equilibrium].
    Eschner J; Fodor L; Ahnefeld FW
    Infusionsther Klin Ernahr; 1976 Apr; 3(2):98-104. PubMed ID: 965083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 16. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
    Vitolo E; Gambini E; Larovere MT; Rusconi F; Vitali GM
    Boll Soc Ital Cardiol; 1979; 24(7):775-7. PubMed ID: 554665
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of potassium canrenoate in cardiosurgery].
    Tufano R; Scopa M; Brando G; Leone D
    Minerva Anestesiol; 1981 Apr; 47(4):149-54. PubMed ID: 7242963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of K canrenoate in the treatment of secondary hyperaldosteronism].
    Tartagni F; Pasetti L; Ambrosioni E; Magnani B
    G Clin Med; 1979 Mar; 60(3):196-206. PubMed ID: 520727
    [No Abstract]   [Full Text] [Related]  

  • 20. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.